Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
PrincipalTel Aviv, Israel
PartnerTel Aviv, Israel
SupportTel Aviv, Israel
GeneTech Inc. has been acquired by Eurofins
Noritsu Koki Co., Ltd. has sold GeneTech Inc. to Eurofins Clinical Testing Holding Lux S.à r.l.Learn more
Dental Holding has been acquired by Advantage Partners
Noritsu Koki Co., Ltd. has sold Dental Holding Inc. to Advantage Partners Inc.Learn more
MediCa group has been acquired by Repharm
CGP Management has sold MediCa group, the largest private provider of healthcare services in Lithuania, to Repharm.Learn more